We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | NASDAQ:ESPR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.44% | 2.12 | 2.12 | 2.13 | 40,334 | 12:38:24 |
| Table of Contents | | | |||||
| Prospectus Supplement | | | |||||
| | | | | | PAGE | | |
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-10 | | | |
| | | | | S-12 | | | |
| | | | | S-13 | | | |
| | | | | S-15 | | | |
| | | | | S-16 | | | |
| | | | | S-20 | | | |
| | | | | S-27 | | | |
| | | | | S-27 | | | |
| | | | | S-27 | | | |
| | | | | S-28 | | | |
| Prospectus | | | | | | | |
| | | | | | PAGE | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Historical net tangible book value per share as of September 30, 2023
|
| | | | | | | | | $ | (3.59) | | |
|
Increase in pro forma net tangible book value per share attributable to this offering
|
| | | | | | | | | | | | |
|
Pro forma net tangible book value per share after giving effect to this offering
|
| | | | | | | | | | | | |
|
Dilution in net tangible book value per share to investors participating in this offering
|
| | | | | | | | | $ | | | |
|
Underwriter
|
| |
Number of
Shares |
| |||
Jefferies LLC
|
| | | | | | |
Total
|
| | | | | | |
|
| | |
Per Share
|
| |
Total
|
| ||||||||||||||||||
| | |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| ||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Underwriting discounts and commissions paid by us
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 13 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | |
1 Year Esperion Therapeutics Chart |
1 Month Esperion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions